Publications
Find coverage of the latest original articles on scleroderma, focusing on those with data on therapeutic interventions and those that have clinical impact.
Sponsored by Boehringer Ingelheim.
December 2025
A composite endpoint for systemic sclerosis–associated interstitial lung disease: association with mortality in two clinical trial cohorts
Respir Res. 2025;26(1):337 DOI : 10.1186/s12931-025-03401-8
Volkmann et al. validated a composite endpoint for systemic sclerosis–associated interstitial lung disease (SSc-ILD) using data from SLS II and compared performance with the SLS I cohort. The composite endpoint showed generalisability and demonstrated greater sensitivity for detecting treatment effects than forced vital capacity (FVC) alone.
Keywords:
June 2025
Tocilizumab in systemic sclerosis: A randomised, double-blind, placebo-controlled, Phase 3 trial
Lancet Respir Med 2020;8:963–74 DOI: 10.1016/S2213-2600(20)30318-0.
Khanna et al. evaluated tocilizumab in patients with early diffuse cutaneous systemic sclerosis in the focuSSced trial. The primary endpoint of improved skin fibrosis was not met, but a key secondary outcome showed that tocilizumab significantly preserved lung function compared with placebo.